Oncolytics Biotech Inc (ONCY)

Nov 25, 2025

This Canadian biotech stock is tackling pancreatic Cancer - Cantech Letter

Nov 25, 2025

Nov 24, 2025

Are Analysts Too Optimistic About Nagreeka Capital Infrastructure Ltds Revenue GrowthGap Up/Gap Down Analysis & Achieve Consistent Profits - earlytimes.in

Nov 24, 2025

Nov 21, 2025

Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital - The Globe and Mail

Nov 21, 2025

Nov 21, 2025

Can Oncolytics Biotech Inc. stock sustain free cash flow growthJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com

Nov 21, 2025

Nov 21, 2025

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - BioSpace

Nov 21, 2025

Nov 21, 2025

Can Oncolytics Biotech Inc. stock attract ESG capital inflowsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com

Nov 21, 2025

Nov 20, 2025

Identifying reversal signals in Oncolytics Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Nigeria

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - TipRanks

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia

Nov 20, 2025

Nov 20, 2025

FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media

Nov 20, 2025

Nov 20, 2025

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace

Nov 20, 2025

Nov 19, 2025

Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com

Nov 19, 2025

Nov 19, 2025

What recovery options are there for Oncolytics Biotech Inc.Quarterly Trade Report & Expert Approved Momentum Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Will Oncolytics Biotech Inc. outperform the marketWeekly Stock Summary & Community Consensus Stock Picks - newser.com

Nov 19, 2025

Nov 19, 2025

Using data tools to time your Oncolytics Biotech Inc. exitTreasury Yields & Low Drawdown Trading Techniques - newser.com

Nov 19, 2025

Nov 19, 2025

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - sharewise.com

Nov 19, 2025

Nov 19, 2025

Backtesting results for Oncolytics Biotech Inc. trading strategies2025 Technical Patterns & Precise Buy Zone Identification - newser.com

Nov 19, 2025

Nov 19, 2025

Stocks in play: Oncolytics Biotech Inc - The Globe and Mail

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Desig - GuruFocus

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design - MarketScreener

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 - Investing.com India

Nov 19, 2025

Nov 19, 2025

Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer - Seeking Alpha

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - MarketScreener

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech rises as US FDA clears path for pancreatic cancer trial - TradingView

Nov 19, 2025

Nov 19, 2025

Oncolytics (ONCY) and FDA Align on Phase 3 Pelareorep Study Desi - GuruFocus

Nov 19, 2025

Nov 19, 2025

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech Aligns with FDA for Pivotal Pancreatic Cancer Study - TipRanks

Nov 19, 2025

Nov 19, 2025

Oncolytics Biotech aligns with FDA on pivotal study design for pelareorep in first-line pancreatic cancer - MarketScreener

Nov 19, 2025

Nov 19, 2025

Will Oncolytics Biotech Inc. stock keep outperforming rivalsWeekly Investment Summary & Fast Moving Trade Plans - newser.com

Nov 19, 2025

Nov 19, 2025

Using Ichimoku Cloud for Oncolytics Biotech Inc. technicalsDollar Strength & Growth Oriented Trade Recommendations - newser.com

Nov 19, 2025

Nov 18, 2025

Heatmap analysis for Oncolytics Biotech Inc. and competitors2025 Risk Factors & Technical Buy Zone Confirmations - newser.com

Nov 18, 2025

Nov 18, 2025

Analyzing Oncolytics Biotech Inc. with risk reward ratio chartsWeekly Gains Report & Community Verified Trade Alerts - newser.com

Nov 18, 2025

Nov 18, 2025

Why analysts remain bullish on Oncolytics Biotech Inc. stock2025 Earnings Surprises & Verified Entry Point Signals - newser.com

Nov 18, 2025

Nov 18, 2025

Oncolytics Biotech (NASDAQ:ONCY) Price Target Raised to $10.00 - MarketBeat

Nov 18, 2025

Nov 17, 2025

Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - TipRanks

Nov 17, 2025

Nov 17, 2025

Oncolytics Biotech stock price target doubled to $10 by H.C. Wainwright - Investing.com South Africa

Nov 17, 2025

Nov 17, 2025

Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright | - GuruFocus

Nov 17, 2025

Nov 17, 2025

The 5-Minute Investor Podcast, Ep. 37: Cancer-fighting stocks | 2025-11-17 | Investing News - Stockhouse

Nov 17, 2025

Nov 17, 2025

Why Oncolytics Biotech Inc. is moving today2025 Geopolitical Influence & Low Risk High Win Rate Picks - newser.com

Nov 17, 2025